Jury awards Abu Ghraib detainees $42 million, holds contractor responsible
Chris Wallace is leaving CNN. He says he wants to see what the new media environment has to offer
Trump has promised to 'save TikTok'. What happens next is less clear
Painter Frank Auerbach, who fled the Nazis and became a major artist, dies at 93
Ecuador international soccer player Marco Angulo dies aged 22 following car crash
Wall Street makes wagers on the likely winners and losers in a second Trump term
Boeing says it will take several weeks to resume production of planes after the strike
Joel Embiid set to return to slumping 76ers team in need of his presence
(Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
EMA said new data raise serious concerns about the safety of Oxbryta and added that the authorization, marketing and supply of the medicine be suspended until all the available data have been assessed in the ongoing review.
Late on Wednesday, Pfizer said it was withdrawing Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
